RxDoctor Payments Data

Abby Bunnell, OD

Optometrist · Bloomington, MNNPI 1629701099

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $2,083 of the $2,764 with a category attached, or 75.3%. Carl Zeiss Meditec USA, Inc. accounts for 84.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $2,361 and has fallen 87.5% since, to $295 in 2025. Among optometrist clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,764in general payments, 2019–2025

Across 18 payments — averaging $153.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$2K
  • Glaukos Corporation$154
  • Alcon$70
  • Harrow Eye, LLC$47
  • Oyster Point Pharma, Inc.$45
  • Johnson & Johnson Vision Care, Inc.$35
  • plus $74 from 4 others

What the payments were for

  • Travel & lodging$2,08375%
  • Food & beverage$68125%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,764 in reported general payments places this provider in the 90th percentile of 826 optometrist providers in Minnesota.

See all optometrist providers in Minnesota

Medicare billing

Part B allowed, 2024
$56,599
Medicare patients
275
Services billed
657

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate16$16,196
Bromfenac Sodium12$4,190
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$2,797
Prednisolone Acetate63$2,332
Latanoprost118$2,110
Timolol Maleate55$611
Brimonidine Tartrate59$485
MoxifloxacinMoxifloxacin Hcl25$464
Ketorolac Tromethamine11$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$45$16,19616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 826 optometrist providers in Minnesota.

Other optometrist in Bloomington

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →